



DOCKET NO.: MOR-0251/HD0003US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Luigi Grasso, et al.

Application No.: 10/714,228

Filing Date: November 14, 2003

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

For: METHODS OF GENERATING HIGH-PRODUCTION OF ANTIBODIES  
FROM HYBRIDOMAS CREATED BY AN IN VITRO IMMUNIZATION

DATE OF DEPOSIT: *March 23, 2004*

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE UNITED STATES PATENT AND  
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,  
VA 22313-1450.

*Elizabeth A. McLoud*

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;  
or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☒ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


EXCEPT THAT:

- ☒ In view of the voluminous nature of references **3, 27, 28, 49, 61 and 67**, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
  - ☐ Copies of references **[list as appropriate]** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. \_\_\_\_\_, filed \_\_\_\_\_.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ An English language abstract has been provided for reference **246** which is not in the English language.

Date: March 23, 2004

  
Felicity E. Groth  
Registration No. 47,042

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. MOR-0251/ HD0003US		Application No. 10/714,228	
	Applicant Luigi Grasso, et al.			
	Filing Date November 14, 2003		Group Not Yet Assigned	
	Confirmation No. Not Yet Assigned			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

/KAC/	1	Allen, D.J., et al., "MutS mediates heteroduplex loop formation by a translocation mechanism," <i>EMBO J.</i> , 1997, 16(14), 4467-4476
	2	Antoni, G., et al., "An interactive computer program for the determination of the binding constants of monoclonal antibodies by non-linear regression analysis of radioimmunoassay data," <i>J. of Immunol. Meth.</i> , 1985, 83, 61-68
*	3	Ausubel, et al., Current Protocols in Molecular Biology, <i>John Wiley &amp; Sons, NY</i> , 1998
	4	Belmont, P., et al., "Synthesis and study of a new adenine—acridine tandem, inhibitor of exonuclease III," <i>Bioorg. Med. Chem. Lett.</i> , 2000, 10, 293-295
	5	Bjornson, K.P., et al., "Modulation of MutS ATP hydrolysis by DNA cofactors," <i>Biochem.</i> 2000, 39, 3176-3183
	6	Borrebaeck, C.A.K., "Human mAbs produced by primary <i>in-vitro</i> , immunization," <i>Immunol. Today</i> , 1988, 9(11), 355-359
	7	Brown, J.P., et al., "Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies," <i>J. Biol. Chem.</i> , June 10, 1980, 255(11), 4980-4983
	8	Brown, J.P., et al., "Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies," <i>J. of Immunol.</i> , August 1981, 127(2), 539-546
	9	Chino, M., et al., "Effect of a novel antibiotic, heliquinomycin, on DNA helicase and cell growth," <i>J. Antibiot. (Tokyo)</i> , May 1998, 51(5), 480-486
↓	10	Cole, S.P.C., et al., "The EBV-hybridoma technique and its application to human lung cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , <i>Alan R. Liss, Inc.</i> , 1985, 77-96

**EXAMINER** /Karen A. Canella, Ph.D./

**DATE CONSIDERED** 06/04/2007

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0251/ HD0003US	Application No. 10/714,228
		Applicant Luigi Grasso, et al.	
		Filing Date November 14, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
/KAC/	11	Cote, R.J., et al., "Generation of human monoclonal antibodies reactive with cellular antigens," <i>Proc. Natl. Acad. Sci. USA</i> , April 1983, 80, 2026-2030	
	12	Crooke, S.T., et al., "Pharmacokinetic properties of several novel oligonucleotide analogs in mice," <i>J. Pharmacol. Exp. Ther.</i> , 1996, 277(2), 923-937	
	13	Emery, S.C., et al., "Strategies for humanizing antibodies," in: Antibody Engineering, Borrebaeck, C.A.K. (Ed.), <i>Oxford University Press, NY</i> , 1995, 159-183	
	14	Englisch, U., et al., "Chemically modified oligonucleotides as probes and inhibitors," <i>Angewandte Chemie (International Edition)</i> , June 1991, 30(6), 613-722	
	15	Fiedler, U., et al., "High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds," <i>Bio/Technology</i> , October 1995, 13, 1090-1093	
	16	Fire, A., et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," <i>Nature</i> , February 19, 1998, 391 806-811	
	17	Gait, M.J., "Oligoribonucleotides as drugs?," Antisense Research and Applications, Crooke, S.T., et al. (Eds.), CRC Press, 1993, Chapt. 16, 289-302	
	18	Galfre, G., et al., "Antibodies to major histocompatibility antigens produced by hybrid cell lines," <i>Nature</i> , April 7, 1977, 266, 550-552	
	19	Galio, L., et al., "ATP hydrolysis-dependent formation of a dynamic ternary nucleoprotein complex with MutS and MutL," <i>Nucl. Acids Res.</i> , 1999, 27(11), 2325-2331	
↓	20	Geftter, M.L., et al., "A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells," <i>Somatic Cell Genet.</i> , 1977, 3(2), 231-236	
EXAMINER		/Karen A. Canella, Ph.D./	DATE CONSIDERED 06/04/2007

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0251/ HD0003US	Application No. 10/714,228
		Applicant Luigi Grasso, et al.	
		Filing Date November 14, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
/KAC/	21	Glaser, V., "Can ReoPro repolish tarnished monoclonal therapeutics?," <i>Nat. Biotechnol.</i> , October 1996, 14, 1216-1217	
	22	Graham, F.L., et al., "Characteristics of a human cell line transformed by DNA from human adenovirus type 5," <i>J. Gen. Virol.</i> , 1977, 36, 59-72	
	23	Grishok, A., et al., "Genetic requirements for inheritance of RNAi in <i>C. elegans</i> ," <i>Science</i> , March 31, 2001, 287, 2494-2497	
	24	Horii, A., et al., "Cloning, characterization and chromosomal assignment of the human genes homologous to yeast PMS1, a member of mismatch repair genes," <i>Biochem. Biophys. Res. Commun.</i> , 1994, 204(3), 1257-1264	
	25	Huang, Y.-C., et al., "N-ethylmaleimide profiling of yeast NADP-dependent isocitrate dehydrogenase," <i>Arch. Biochem. Biophys.</i> , January 10, 1995, 316(1), 485-492	
	26	Kabanov, A.V., et al., "A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells," <i>FEBS Lett.</i> , 1990, 259, 327-330	
*	27	Kaufman, et al. (Eds.), Handbook of Molecular and Cellular Methods in Biology and Medicine, <i>CRC Press, Boca Raton</i> , 1995	
*	28	Kenneth, in Monoclonal Antibodies: A New Dimension in Biological Analyses, <i>Plenum Publishing Corp., NY, NY</i> , 1980	
	29	Khazaeli, M.B., et al., "Human immune response to monoclonal antibodies," <i>J. of Immunother.</i> , 1994, 15, 42-52	
↓	30	Kitagawa, T., et al., "Enzyme coupled immunoassay of insulin using a novel coupling reagent," <i>J. Biochem.</i> , 1976, 79, 233-236	
EXAMINER /Karen A. Canella, Ph.D./		DATE CONSIDERED 06/04/2007	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0251/ HD0003US	Application No. 10/714,228
		Applicant Luigi Grasso, et al.	
		Filing Date November 14, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
/KAC/	31	Köhler, G., et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , August 7, 1975, 256, 495-497	
	32	Kozbor, D., et al., "The production of monoclonal antibodies from human lymphocytes," <i>Immunology Today</i> , 1983, 4(3), 72-79	
	33	Kroschwitz, J.I.(Ed.), "Polynucleotides," The Concise Encyclopedia of Polymer Science and Engineering, <i>John Wiley &amp; Sons</i> , 1990, 858-859	
	34	Kukhanova, M., et al., "Unique inhibitory effect of 1-(2'-deoxy-2'-fluoro-β-L-arabinofuranosyl)-5-methyluracil 5'-triphosphate on Epstein-barr virus nd human DNA polymerases," <i>Biochem. Pharmacol.</i> , 1998, 55, 1181-1187	
	35	Kuwakado, K., et al., "Aphidicolin potentiates apoptosis induced by arabinosyl nucleosides in human myeloid leukemia cell lines," <i>Biochem. Pharmacol.</i> , 1993, 46(11), 1909-1916	
	36	Lehninger, A.L., "The molecular basis of cell structure and function," Biochemistry, 2 <sup>nd</sup> Ed., <i>Worth Publishers, Inc.</i> , 1975, 72-77	
	37	Lerner, E.A., "How to make a hybridoma," <i>Yale J. Biol. and Med.</i> , 1981, 54, 387-402	
	38	Letsinger, R.L., et al., "Cholesteryl-conjugated oligonucleotides: synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture," <i>Proc. Natl. Acad. Sci. USA</i> , 1989, 86, 6553-6556	
	39	Manoharan, M., et al., "Chemical modifications to improve uptake and bioavailability of antisense oligonucleotides," <i>Ann. NY Acad. Sci.</i> , 1992, 660, 306-309	
↓	40	Manoharan, M., et al., "Introduction of a lipophilic thioether tether in the mirror groove of nucleic acids for antisense applications," <i>Bioorg. Med. Chem. Let.</i> , 1993, 3, 2765-2770	
EXAMINER /Karen A. Canella, Ph.D./		DATE CONSIDERED 06/04/2007	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0251/ HD0003US	Application No. 10/714,228
		Applicant Luigi Grasso, et al.	
		Filing Date November 14, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
/KAC/	41	Manoharan, M., et al., "Cholic acid-oligonucleotide conjugates for antisense applications," <i>Bioorg. Med. Chem. Lett.</i> , <b>1994</b> , <i>4</i> , 1053-1060	
	42	Manoharan, M., et al., "Oligonucleotide conjugates: alteration of the pharmacokinetic properties of antisense agents," <i>Nucleosides &amp; Nucleotides</i> , <b>1995</b> , <i>14</i> , 969-973	
	43	Manoharan, M., et al., "Lipidic nucleic acids," <i>Tetrahedron Lett.</i> , <b>1995</b> , <i>36</i> (21), 3651-3654	
	44	Martin, v.-P., et al., "Ein neuer zugang zu 2'-O-alkylribonucleosiden und eigenschaften deren oligonucleotide," <i>Helv. Chim. Acta</i> , <b>1995</b> , <i>78</i> , 486-504 (English abstract)	
	45	Martin, S.J., et al., "Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis," <i>J. of Immunol.</i> , September 15, <b>1990</b> , <i>145</i> (6), 1859-1867	
	46	Marx, J., "Interfering with gene expression," <i>Science</i> , May 26, <b>2000</b> , <i>288</i> , 1370-1372	
	47	Mather, J.P., "Establishment and characterization of two distinct mouse testicular epithelial cell lines," <i>Biol. of Reprod.</i> , <b>1980</b> , <i>23</i> , 243-252	
	48	Mather, J.P., et al., "culture of testicular cells in hormone-supplemented serum-free medium," <i>Annals N.Y. Acad. Sci.</i> , <b>1982</b> , <i>383</i> , 44-68	
*	49	McPherson (Ed.), <i>Directed Mutagenesis: A Practical Approach</i> , IRL Press, Oxford, <b>1991</b>	
↓	50	Mishra, R.K., et al., "Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-medicated delivery," <i>Biochim. Et Biophysica</i> , <b>1995</b> , <i>1264</i> , 229-237	
EXAMINER		/Karen A. Canella, Ph.D./	DATE CONSIDERED 06/04/2007

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0251/ HD0003US	Application No. 10/714,228
		Applicant Luigi Grasso, et al.	
		Filing Date November 14, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
/KAC/	51	Müller, R., "calculation of average antibody affinity in anti-hapten sera from data obtained by competitive radioimmunoassay," <i>J. Immunol. Meth.</i> , 1980, 34, 345-352	
	52	Neuberger, M., et al., "Mice perform a human repertoire," <i>Nature</i> , March 6, 1997, 386, 25-26	
	53	Nicolaidis, N.C., et al., "Genomic organization of the human <i>PMS2</i> gene family," <i>Genomics</i> , 1995, 30, 195-206	
	54	Nicolaidis, N.C., et al., "A naturally occurring <i>hPMS2</i> mutation can confer a dominant negative mutator phenotype," <i>Mol. Cell. Biol.</i> , XP-002165242, March 1998, 18(3), 1635-1641	
	55	Nielsen, P.E., et al., "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polymide," <i>Science</i> , 1991, 254, 1497-1500	
	56	Oberhauser, B., et al., "Effective incorporation of 2'-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol," <i>Nucl. Acids Res.</i> , 1992, 20(3), 533-538	
	57	Ono, K., et al., "Inhibition of DNA polymerase $\alpha$ by 2',3'-dideoxyribonucleoside 5'-triphosphates: effect of manganese ion," <i>Biomed. &amp; Pharmacother.</i> , 1984, 38, 382-389	
	58	Reff, M.E., "High-level production of recombinant immunoglobulins in mammalian cells," <i>Curr. Opin. Biotechnol.</i> , 1993, 4, 573-576	
	59	Saez-Llorens, X., et al., "Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia," <i>Pediat. Infect. Disc. J.</i> , September 1998, 17(9), 787-791	
↓	60	Saison-Behmoaras, T., et al., "Short modified antisense oligonucleotides directed against <i>Ha-ras</i> point mutation induced selective cleavage of the mRNA and inhibit T24 cells proliferation," <i>EMBO J.</i> , 1991, 10(5), 1111-1118	
EXAMINER /Karen A. Canella, Ph.D./		DATE CONSIDERED 06/04/2007	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0251/ HD0003US	Application No. 10/714,228
		Applicant Luigi Grasso, et al.	
		Filing Date November 14, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
* /KAC/	61	Sambrook, et al., <i>Molecular Cloning: A Laboratory Manual</i> , 2 <sup>nd</sup> Ed., <i>Cold Spring Harbor Laboratory Press, Plainview, NY</i> , 1989	
	62	Sanghvi, Y.S., "Heterocyclic base modifications in nucleic acids and their applications in antisense oligonucleotides," <i>Antisense Research and Applications</i> , Crooke, et al. (Eds.), <i>CRC Press</i> , 1993, 273-288	
	63	Sharp, P.A., et al., "RNA Interference," <i>Science</i> , March 31, 2000, 287, 2431-2433	
	64	Shea, R.G., et al., "Synthesis, hybridization properties and antiviral activity of lipidoligodeoxynucleotide conjugates," <i>Nucl. Acids Res.</i> , 1990, 18, 3777-3783	
	65	Shield, C.F., III, et al., "A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation," <i>Am. J. Kidney Dis.</i> , June 1996, 27(6), 855-864	
	66	Svinarchuk, F.P., et al., "Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups," <i>Biochimie</i> , 1993, 79, 49-54	
*	67	Thorell, et al., <i>Radioimmunoassay and Related Techniques: Methodology and Clinical Applications</i> , 1978	
	68	Urlaub, G., et al., "Isolation of chinese hamster cell mutants deficient in dihydrofolate," <i>Proc. Natl. Acad. Sci. USA</i> , July 1980, 77(7), 4216-4220	
	69	Waldman, T., et al., "p21 is necessary for the p53-mediated G <sub>1</sub> arrest in human cancer cells," <i>Cancer Res.</i> , November 15, 1995, 55, 5187-5190	
↓	70	Weiner, L.M., "Monoclonal antibody therapy of cancer," <i>Semin. In Oncol.</i> , October 1999, 26(5), 43-51	
EXAMINER /Karen A. Canella, Ph.D./		DATE CONSIDERED 06/04/2007	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0251/ HD0003US	Application No. 10/714,228
		Applicant Luigi Grasso, et al.	
		Filing Date November 14, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
/KAC/	71	Yeh, M.-Y., et al., "A cell-surface antigen which is present in the ganglioside fraction and shared by human melanomas," <i>Int. J. Cancer</i> , 1982, 29, 269-275	
↓	72	Yeh, M.-Y., et al., "Cell surface antigens of human melanoma identified by monoclonal antibody," <i>Proc. Natl. Acad. Sci. USA</i> , June 1979, 76(6), 2927-2931	
↓	73	Zafiropoulos, A., et al., "Induction of antigen-specific isotype switching by in vitro immunization of human naïve B lymphocytes," <i>J. of Immunological Methods</i> , 1997, 200, 181-190	
<b>EXAMINER</b> /Karen A. Canella, Ph.D./		<b>DATE CONSIDERED</b> 06/04/2007	

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	74	3,687,808	08/29/72	Merigan, Jr., et al.		
	75	4,376,110	03/08/83	David, et al.	436	548
	76	4,469,863	09/04/84	Ts'o, et al.	536	27
	77	4,476,301	10/09/84	Imbach, et al.	536	27
	78	4,587,044	05/06/86	Miller, et al.	530	211
	79	4,605,735	08/12/86	Miyoshi, et al.	536	27
	80	4,667,025	05/19/87	Miyoshi, et al.	536	27
	81	4,720,459	01/19/88	Winkelhake	435	240.2
	82	4,762,779	08/09/88	Snitman	435	6
	83	4,789,737	12/06/88	Miyoshi, et al.	536	27
	84	4,824,941	04/25/89	Gordon, et al.	530	403
	85	4,828,979	05/09/89	Klevan, et al.	435	6
	86	4,835,263	05/30/89	Nguyen, et al.	536	27
	87	4,845,205	07/04/89	Huynh Dinh, et al.	536	28
	88	4,876,335	10/24/89	Yamane, et al.	536	27
	89	4,904,582	02/27/90	Tullis	435	6
↓	90	4,948,882	08/14/90	Ruth	536	27

**EXAMINER**

/Karen A. Canella, Ph.D./

**DATE CONSIDERED**

06/04/2007

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	91	4,958,013	09/18/90	Letsinger	536	27
	92	4,981,957	01/01/91	Lebleu, et al.	536	27
	93	5,013,830	05/07/91	Ohtsuka, et al.	536	27
	94	5,023,243	06/11/91	Tullis	514	44
	95	5,034,506	07/23/91	Summerton	528	391
	96	5,082,830	01/21/92	Brakel, et al.	514	44
	97	5,109,124	04/28/92	Ramachandran, et al.	536	27
	98	5,112,963	05/12/92	Pieles, et al.	536	27
	99	5,118,800	06/02/92	Smith, et al.	536	23
	100	5,118,802	06/02/92	Smith, et al.	536	27
	101	5,130,302	07/14/92	Spielvogel, et al.	514	45
	102	5,134,066	07/28/92	Rogers, et al.	435	91
	103	5,138,045	08/11/92	Cook, et al.	536	27
	104	5,149,797	09/22/92	Pederson, et al.	536	27
	105	5,166,315	11/24/92	Summerton, et al.	528	406
	106	5,175,273	12/29/92	Bischofberger, et al.	536	27
↓	107	5,177,196	01/05/93	Meyer, Jr., et al.	536	22.1

**EXAMINER** /Karen A. Canella, Ph.D./

**DATE CONSIDERED** 06/04/2007

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	108	5,185,444	02/09/93	Summerton, et al.	544	81
	109	5,188,897	02/23/93	Suhadolnik, et al.	428	402.2
	110	5,194,599	03/16/93	Froehler, et al.	536	26.72
	111	5,214,134	05/25/93	Weis, et al.	536	25.3
	112	5,214,136	05/25/93	Lin, et al.	514	44
	113	5,216,141	06/01/93	Benner	536	27.13
	114	5,218,105	06/08/93	Cook, et al.	536	25.31
	115	5,220,007	06/15/93	Pederson, et al.	536	23.1
	116	5,235,033	08/10/93	Summerton, et al.	528	391
	117	5,245,022	09/14/93	Weis, et al.	536	24.5
	118	5,254,469	10/19/93	Warren, III, et al.	435	188
	119	5,256,775	10/26/93	Froehler	536	25.6
	120	5,258,506	11/02/93	Urdea, et al.	536	23.1
	121	5,262,536	11/16/93	Hobbs, Jr.	546	25
	122	5,264,423	11/23/93	Cohen, et al.	514	44
	123	5,264,562	11/23/93	Mateucci	536	23.1
	124	5,264,564	01/04/94	Cohen, et al.	514	44
	125	5,272,250	12/21/93	Spielvogel, et al.	530	300
<b>EXAMINER</b> /Karen A. Canella, Ph.D./				<b>DATE CONSIDERED</b> 06/04/2007		

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	126	5,276,019	01/04/94	Cohen, et al.	514	44
	127	5,276,423	01/04/94	Breit, et al.	338	308
	128	5,278,302	01/11/94	Caruthers, et al.	536	24.5
	129	5,286,717	02/15/94	Cohen, et al.	514	44
	130	5,292,873	03/08/94	Rokita, et al.	536	24.3
	131	5,317,098	05/31/94	Shizuya, et al.	536	23.1
	132	5,319,080	06/07/94	Leumann	536	27.1
	133	5,321,131	06/14/94	Agrawal, et al.	536	25.34
	134	5,359,044	10/25/94	Cook, et al.	536	23.1
	135	5,366,878	11/22/94	Pederson, et al.	435	91.3
	136	5,367,066	11/22/94	Urdea, et al.	536	24.3
	137	5,371,241	12/06/94	Brush	549	220
	138	5,391,723	02/21/95	Priest	536	23.1
	139	5,393,878	02/28/95	Leumann	536	28.2
	140	5,399,676	03/21/95	Froehler	536	23.1
	141	5,403,711	04/04/95	Walder, et al.	435	6
	142	5,405,938	04/11/95	Summerton, et al.	528	406
✓	143	5,405,939	04/11/95	Suhadolnik, et al.	530	322
<b>EXAMINER</b> /Karen A. Canella, Ph.D./				<b>DATE CONSIDERED</b> 06/04/2007		



**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	144	5,414,077	05/09/95	Lin, et al.	536	24.3
	145	5,416,203	05/16/95	Letsinger	536	25.34
	146	5,432,272	07/11/95	Benner	536	25.3
	147	5,434,257	07/18/95	Matteucci, et al.	536	24.3
	148	5,446,137	08/29/95	Maag, et al.	536	23.1
	149	5,451,463	09/19/95	Nelson, et al.	428	402
	150	5,453,496	09/26/95	Caruthers, et al.	536	24.5
	151	5,455,233	10/03/95	Spielvogel, et al.	514	44
	152	5,457,187	10/10/95	Gmeiner, et al.	536	25.5
	153	5,459,255	10/17/95	Cook, et al.	536	27.13
	154	5,466,677	11/14/95	Baxter, et al.	514	44
	155	5,466,786	11/14/95	Buhr, et al.	536	26.26
	156	5,470,967	11/28/95	Huie, et al.	536	24.3
	157	5,476,925	12/19/95	Letsinger, et al.	536	23.1
	158	5,484,908	01/16/96	Froehler, et al.	536	24.31
	159	5,486,603	01/23/96	Buhr	536	24.3
✓	160	5,489,677	02/06/96	Sanghvi, et al.	536	22.1

EXAMINER /Karen A. Canella, Ph.D./

DATE CONSIDERED 06/04/2007

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	161	5,491,133	02/13/96	Walder, et al.	514	44
	162	5,502,177	03/26/96	Matteucci, et al.	536	26.6
	163	5,510,475	04/23/96	Agrawal, et al.	536	24.3
	164	5,512,439	04/30/96	Hornes, et al.	435	6
	165	5,512,667	04/30/96	Reed, et al.	536	24.31
	166	5,514,785	05/07/96	Van Ness, et al.	536	22.1
	167	5,519,126	05/21/96	Hecht	536	24.3
	168	5,519,134	05/21/96	Acevedo, et al.	544	243
	169	5,525,465	06/11/96	Haralambidis, et al.	435	6
	170	5,525,711	06/11/96	Hawkins, et al.	536	22.1
	171	5,527,899	06/18/96	Froehler	536	25.3
	172	5,530,101	06/25/96	Queen, et al.	530	387.3
	173	5,536,821	07/16/96	Agrawal, et al.	536	22.1
	174	5,539,082	07/23/96	Nielsen, et al.	530	300
	175	5,541,306	07/30/96	Agrawal, et al.	536	22.1
	176	5,541,307	07/30/96	Cook, et al.	536	23.1
	177	5,541,313	07/30/96	Ruth	536	24.3
<b>EXAMINER</b> /Karen A. Canella, Ph.D./				<b>DATE CONSIDERED</b> 06/04/2007		

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	178	5,545,730	08/13/96	Urdea, et al.	536	28.51
	179	5,550,111	08/27/96	Suhadolnik, et al.	514	44
	180	5,552,538	09/03/96	Urdea, et al.	536	24.3
	181	5,552,540	09/03/96	Haralambidis	536	25.34
	182	5,561,225	10/01/96	Maddry, et al.	536	23.1
	183	5,563,253	10/08/96	Agrawal, et al.	536	22.1
	184	5,565,350	10/15/96	Kmiec	435	172.3
	185	5,565,552	10/15/96	Magda, et al.	534	11
	186	5,565,555	10/15/96	Froehler, et al.	536	26.22
	187	5,567,810	10/22/96	Weis, et al.	536	25.3
	188	5,567,811	10/22/96	Misiura, et al.	536	25.34
	189	5,571,799	11/05/96	Tkachuk, et al.	514	47
	190	5,574,142	11/12/96	Meyer, Jr., et al.	536	23.1
	191	5,576,427	11/19/96	Cook, et al.	536	23.1
	192	5,578,717	11/26/96	Urdea, et al.	536	26.1
	193	5,578,718	11/26/96	Cook, et al.	536	27.21
✓	194	5,580,731	10/03/96	Chang, et al.	435	6

**EXAMINER** /Karen A. Canella, Ph.D./

**DATE CONSIDERED** 06/04/2007

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	195	5,585,481	12/17/96	Arnold, Jr., et al.	536	25.33
	196	5,587,361	12/24/96	Cook, et al.	514	44
	197	5,587,371	12/24/96	Sessler, et al.	514	185
	198	5,587,469	12/24/96	Cook, et al.	536	23.1
	199	5,591,584	01/07/97	Chang, et al.	435	6
	200	5,591,722	01/07/97	Montgomery, et al.	514	45
	201	5,594,121	01/14/97	Froehler, et al.	536	23.5
	202	5,595,726	01/21/97	Magda, et al.	424	9.61
	203	5,596,086	01/21/97	Matteucci, et al.	536	22.1
	204	5,596,091	01/21/97	Switzer	536	24.5
	205	5,597,696	01/28/97	Linn, et al.	435	6
	206	5,597,909	01/28/97	Urdea, et al.	536	24.3
	207	5,599,923	02/04/97	Sessler, et al.	540	145
	208	5,599,928	02/04/97	Hemmi, et al.	540	474
	209	5,602,240	02/11/97	De Mesmaeker, et al.	536	22.1
	210	5,608,046	03/04/97	Cook, et al.	536	23.1
✓	211	5,610,289	03/11/97	Cook, et al.	536	25.34

EXAMINER /Karen A. Canella, Ph.D./

DATE CONSIDERED 06/04/2007

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	212	5,610,300	03/11/97	Altmann, et al.	544	244
	213	5,614,617	03/25/97	Cook, et al.	536	23.1
	214	5,618,704	04/08/97	Sanghvi, et al.	435	91.5
	215	5,623,065	04/22/97	Cook, et al.	536	23.1
	216	5,623,070	04/22/97	Cook, et al.	536	27.6
	217	5,625,050	04/29/97	Beaton, et al.	536	24.1
	218	5,627,053	05/06/97	Usman, et al.	435	91.1
	219	5,633,360	05/27/97	Bischofberger, et al.	536	22.1
	220	5,639,873	06/17/97	Barascut, et al.	536	25.3
	221	5,645,985	07/08/97	Froehler, et al.	435	6
	222	5,646,265	07/08/97	McGee	536	25.34
	223	5,646,269	07/08/97	Matteucci, et al.	536	26.7
	224	5,652,355	07/29/97	Metlev, et al.	536	24.5
	225	5,652,356	07/29/97	Agrawal	536	24.5
	226	5,658,873	08/19/97	Bertsch-Frank, et al.	510	375
	227	5,663,312	09/02/97	Chaturvedula	536	22.1
	228	5,670,633	09/23/97	Cook, et al.	536	23.1

EXAMINER /Karen A. Canella, Ph.D./

DATE CONSIDERED 06/04/2007

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	229	5,672,697	09/30/97	Buhr, et al.	536	26.7
	230	5,677,437	10/14/97	Teng, et al.	536	23.1
	231	5,677,439	10/14/97	Weis, et al.	536	23.1
	232	5,681,941	10/28/97	Cook, et al.	536	23.1
	233	5,688,941	11/18/97	Cook, et al.	536	25.3
	234	5,700,920	12/23/97	Altmann, et al.	536	221
	235	5,700,922	12/23/97	Cook	536	23.1
	236	5,714,331	02/03/98	Buchardt, et al.	435	6
	237	5,719,262	02/17/98	Buchardt, et al.	530	300
	238	5,721,218	02/24/98	Froehler	514	44
	239	5,750,692	05/12/98	Cook, et al.	544	253
	240	5,763,588	06/09/98	Matteucci, et al.	536	22.1
	241	5,792,608	08/11/98	Swaminathan, et al.	435	6
	242	5,792,747	08/11/98	Schally, et al.	514	12
	243	5,830,653	11/03/98	Froehler, et al.	435	6
	244	6,005,096	12/21/99	Matteucci, et al.	536	26.6
	245	6,146,894	11/14/00	Nicolaides, et al.	435	440

**EXAMINER** /Karen A. Canella, Ph.D./

**DATE CONSIDERED** 06/04/2007

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
MOR-0251/  
HD0003US

Application No.  
10/714,228

Applicant  
Luigi Grasso, et al.

Filing Date  
November 14,  
2003

Group  
Not Yet Assigned

Confirmation No.  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
/KAC/	246	WO 98/39352	09/11/98	PCT	X abstract	
/KAC/	247	WO 99/14226	03/25/99	PCT		
/KAC/	248	PCT/US92/09196	10/23/92	PCT		

**EXAMINER** /Karen A. Canella, Ph.D./

**DATE CONSIDERED** 06/04/2007

**DOCKET NO.: MOR-0251/HD0003US**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In Re Application of:**

**Luigi Grasso**

**Confirmation No.: 4529**

**Application No.: 10/714,228**

**Group Art Unit: 1643**

**Filing Date: November 14, 2003**

**Examiner: Karen A. Canella**

**For: METHODS OF GENERATING HIGH-PRODUCTION OF ANTIBODIES  
FROM HYBRIDOMAS CREATED BY AN *IN VITRO* IMMUNIZATION**

Electronically Filed: May 1, 2007

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or



before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

- ☐ Certification in Accordance with § 1.97(e) is attached; or
- ☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☒ Copies of reference numbers **253 - 261** listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ A copy of reference number **252** on the attached Form PTO 1449 is not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

- ☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

The references cited on the attached PTO-1449 form were cited in the International Search Report dated April 2, 2007 that was received in the corresponding EP application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

Date: April 25, 2007

/Felicity E. Groth/  
Felicity E. Groth  
Registration No. 47,042

**WOODCOCK WASHBURN LLP**  
Cira Centre  
2929 Arch Street, 12th Floor  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. MOR-0251/HD0003US	Application No. 10/714,228
	Applicant Luigi Grasso	
	Filing Date November 14, 2003	Group 1643
	Confirmation No. 4529	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/KAC/	1	2003/143682 equiv to 6,808,894 B1	10/26/04	Nicolaides, et al.	435	69.1,

EXAMINER	/KAC/	/Karen A. Canella, Ph.D./	DATE CONSIDERED	06/04/2007
----------	-------	---------------------------	-----------------	------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications. Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. MOR-0251/HD0003US	Application No. 10/714,228
	Applicant Luigi Grasso	
	Filing Date November 14, 2003	Group 1643
	Confirmation No. 4529	

## FOREIGN PATENT DOCUMENTS

[illegible]

<b>EXAMINER</b> /Karen A. Canella, Ph.D./	<b>DATE CONSIDERED</b> 06/04/2007
---	-----------------------------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. MOR-0251/HD0003US	Application No. 10/714,228
	Applicant Luigi Grasso	
	Filing Date November 14, 2003	Group 1643
	Confirmation No. 4529	

**NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

/KAC/	6	Guzman, J., et al., "In vitro immunization: generation of neutralizing monoclonal antibodies to human interleukin-10," J. of Immunological Methods, 1995, 179(2), 265-268
/KAC/	7	Ho, M.K., et al., "In vitro immunization of human lymphocytes. I. Production of human monoclonal antibodies against bombesin and tetanus toxoid," J. of Immunology, 1985, 135(6), 3831-3838
/KAC/	8	Kim, N., et al., "The role of DNA repair in somatic hypermutation of immunoglobulin genes," J. of Experimental medicine, 1998, 187(11), 1729-1733
/KAC/	9	Martin, A., et al., "Aid and mismatch repair in antibody diversification," Nature Reviews, Immunology, 2002, 2(8), 605-614
/KAC/	10	Pardue, R.L., et al., "Production of monoclonal antibodies against calmodulin by in vitro immunization of spleen cells," J. of Cell Biology, 1983, 96(4), 1149-1154

EXAMINER /Karen A. Canella, Ph.D./

DATE CONSIDERED 06/04/2007



*Idw*

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In Re Application of:**

**Luigi Grasso, et al.**

**Confirmation No.: 4529**

**Application No.: 10/714,228**

**Group Art Unit: 1643**

**Filing Date: November 14, 2003**

**Examiner: Karen A. Canella**

**For: METHODS OF GENERATING HIGH-PRODUCTION OF ANTIBODIES  
FROM HYBRIDOMAS CREATED BY AN IN VITRO IMMUNIZATION**

**DATE OF DEPOSIT:** *July 31, 2006*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

*Heather Kite*

**TYPED NAME:** Heather Kite

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers 249-251 listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).


- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.

The reference(s) cited on the attached PTO-1449 form were cited in the International Search Report dated June 28, 2006, that was received in the corresponding PCT application.


Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: 7/31/06

  
\_\_\_\_\_  
Brian A. Cocca, Ph.D.  
Registration No. 58,583

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439





Sheet 1 of 1

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0251	Application No. 10/714,228
		Applicant Luigi Grasso, et al.	
		Filing Date November 14, 2003	Group 1643
		Confirmation No. 4529	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
/KAC/	249	Spencer, J. et al., "Characteristics of Sequences Around Individual Nucleotide Substitutions I IgV <sub>H</sub> Genes Suggest different GC and AT Mutators," <i>Journal of Immunology</i> , 1999, 162, 6596-6601	
/KAC/	250	Reynaud, C-A. et al., "Mismatch repair and immunoglobulin gene hypermutation: did we learn something?" <i>Immunology Today</i> , November 1999, 20, 522-527	
/KAC/	251	Bigger, C. A. H. et al., "Mutational spectra for polycyclic aromatic hydrocarbons in the <i>supF</i> target gene," <i>Mutation Research</i> , 2000, 450, 75-93	
<b>EXAMINER</b> /Karen A. Canella, Ph.D./		<b>DATE CONSIDERED</b> 06/04/2007	